INTRODUCTION
Diabetic nephropathy is a spectrum of progressive renal lesions secondary to diabetes mellitus ranging from renal hyper filtration to end stage kidney disease and responsible for significant morbidity and mortality among the Diabetic population 1 . It occurs as a microvascular complication of both insulin dependent (IDDM) and non-insulin dependent (NIDDM) diabetes mellitus characterised by persistent proteinuria, decline in glomerular filtration rate (GFR) 2 . The overall prevalence of diabetic nephropathy varies from 20 -40% in diabetic patients 2 . It occurs in 30% of type I diabetics, 5 to 15 years after diagnosis but may be present at diagnosis in type II diabetics, as the time of onset of type II diabetes is often unknown 1 . Diabetic nephropathy is also the most common cause of end stage renal disease (ESRD) and has a devastating impact on morbidity and mortality of patients with diabetes mellitus 1 . Known risk factors for the development of diabetic nephropathy include genetic predisposition, poor glycaemic control, hypertension and smoking 1 . Prevention, early detection and aggressive intervention are needed to retard the progression of diabetic nephropathy to end stage renal failure 1, 2 . The earliest clinical evidence of nephropathy is the presence of microalbuminuria.. Microalbuminuria progresses to overt proteinuria over the next 7 to 10 years. Once overt proteinuria develops, renal function progressively declines and end stage renal failure is reached after about 10 years 1, 2 . Microalbuminuria is a powerful and independent predictor of cardiovascular death 3 . The management of diabetic nephropathy includes good glycaemic control, tight control of blood pressure and reduction of proteinuria with cessation of smoking, lipid control and salt and protein restriction 4 . Therapeutic intervention is intended to prevent or retard the progression of diabetic renal disease as well as to reduce cardiovascular complications 4 . Several small studies have indicated that the combination of ACEI and ARB may have additive effect in lowering blood pressure and proteinuria in diabetic patients with microalbuminuria and overt nephropathy 10 .
Drug utilization studies are conducted frequently all over the world. In developing countries with the constraint of health budget for drugs, it becomes even more meaningful to prescribe drugs rationally. These studies can thus help to set priorities for the rational allocation of health care budgets and can ascertain the role of drugs in society. The present study was undertaken in a tertiary care hospital to evaluate the current drug utilization pattern in patients with Diabetic nephropathy and to facilitate rational use of drugs in such patient population.
MATERIALS AND METHODS
The study began after the approval from the Institutional Ethics Committee. Data was collected from 313 case sheets of Diabetic patients, who got admitted in Nephrology department at Sri Ramachandra Hospital, Chennai, from June 2009 to December 2010 with proteinuria on urine analysis. Later, the detailed analysis of drug utilization pattern was performed statistically. However, we did not include pregnant and lactating mothers and the patients who are on hemodialysis support.
Patients attending outdoors were not considered either. This study was a non interventional observation in nature.
RESULTS:
From the demographic details (Table 1) , male sex appeared to be affected more than female with Diabetic nephropathy (63.2% versus 36.8%). A significant number of patients also had co morbidities like Hypertension (76.9%), Dyslipidemia (61.3%) and Obesity (39.3%). There was lesser number of patients of Type1 DM than Type 2 in our study. Insulin and or oral hypoglycemic agents were universally prescribed among all the patients as anti diabetic therapy (Table 2) . Similarly, all of them received at least one drug that inhibits RAAS (Renin Angiotensin Aldosterone system) in the form of ACE inhibitors (32%) or ARBs (68%). Diuretics and CCBs were prescribed in 55% and 48% respectively. 11 . One of the most common causes of renal disorders associated with proteinuria in our tertiary care hospital is Diabetic nephropathy. Table 1 implies that 63.2 % of patients are males. The reason could be increased smoking habit found among men in India, which would have accelerated the progression of Diabetic and non-diabetic renal disease 12 . In fact 66.5% of patients here had a positive smoking history. Close association with Hypertension, Dyslipidemia and Obesity was also evident.
Type II DM constituted more number of cases than type I here (56.9% vs. 43.1%). This is probably because of early diagnosis and initiation of therapy in the latter, where patients become symptomatic much before than type II.
Since a tight glycemic control is the most important factor to halt the process of nephropathy, all patients were given anti diabetic therapy with either Oral hypoglycemic agents and or Insulin (Table2). Different forms of Insulin were prescribed on the basis of patient's requirement, while Glimepiride appeared to be the most commonly used oral agent.
Due to their established efficacy in Diabetic nephropathy, ACEIs (32%) and ARBs (68%) were the two most frequently utilized drugs in this setup 5.6 . In our study there was practically no patient, who did not get at least one drug from these two groups.
In type I diabetic patients with or without hypertension, ACEIs have been shown to reduce microalbuminuria 5 , while in type II diabetics, ACEIs and more recently ARBs have been shown to reduce microalbuminuria 6 . Clinical trials involving ACEIs and ARBs in Diabetic nephropathy have shown significant reductions in the risk of doubling of plasma creatinine and developing renal failure. These benefits were independent of blood pressure lowering 7, 8 .
There is also clinical evidence regarding the initiation of ACEIs or ARBs even in the settings of moderately severe renal failure. Although, the renal function should be carefully monitored in those patients 9 .
According to a trial done by Brenner, Parving et al, ARBs are better than ACE inhibitors in reno-protection beyond blood pressure control 8 . ARB may produce renoprotective benefits by lowering the fibrogenic cytokine Transforming Growth Factor-β (TGF β), reducing proteinuria, decreasing renal oxidative stress, preserving glomerular and tubulointerstitial structure and reducing the glomerular membrane pore size 6, 8 .
The choice between ACEIs and ARBs depends on the followings conditions; 13  In hypertensive Type I diabetic patients with any degree of albuminuria, ACE inhibitors have been shown to delay the progression of nephropathy.
 In hypertensive Type II diabetic patients with microalbuminuria, ACE inhibitors and ARBs have shown to delay the progression.
 In patients with Type II diabetes, hypertension, macroalbuminuria, and renal insufficiency (serum creatinine >1.5 mg/dl), ARBs have been shown to delay the progression of nephropathy.
ACEIs and ARBs should be used with caution in patients with bilateral renal artery stenosis or renal artery stenosis of a single functioning kidney. ACEIs and ARBs should be started at lower doses in renal failure and titrated gradually to maximal tolerable dose to achieve antiproteinuric effect. Serum potassium and creatinine should be checked prior to and within one to two weeks after initiating an ACEI or ARB as they can occasionally cause worsening of renal function 13 .
Diuretics potentiate the antihypertensive and antiproteinuric effect of ACEIs and ARBs 14 . This explains why Hydrochlorothiazide was prescribed in 55% of our patients.
We also found Calcium channel blockers (CCBs) like Amlodipine and Cilnidipine to be other commonly prescribed agents (table 2), as they have some class specific effect on proteinuria. However, the effect may be variable with different Dihydropyridines (e.g. nifedipine, amlodipine) 15 . Recently, there are clinical evidences in favour of anti proteinuric effect of Cilnidipine 16 . In our study, it was the second commonest CCB used after Amlodipine (Table 4) .
Treatment of hyperlipidemia with lipid lowering drugs like Atorvastatin, smoking cessation, dietary protein restriction, salt restriction also play a major role in halting the progression of diabetic nephropathy. Very recent study has proved the role of Atorvastatin in reduction of renal cholesterol synthesis in rat 17 . Table 5 demonstrates the combination drug therapy used in our tertiary care hospital for diabetic nephropathy. The multifactorial etiologies of the disease suggest that multiinterventional approach is mandatory to halt the progression of renal disorders and for the reversal of renal microvascular complications. Drugs from two or more groups are often combined for this purpose. We observed that ARBs with Diuretics or CCBs are the most frequently utilized drug combination. Table 6 shows the physicians' advice given to the patient with renal disorders associated with proteinuria. Majority of them were advised protein restricted diet and salt restriction. A study by Koya et al has shown that a lowprotein diet could prevent the progression of diabetic nephropathy 18 .
CONCLUSION
Early detection of renal disorders and the adoption of multifactorial interventions targeting the main risk factors (Hypertension, Hyperglycemia, Dyslipidemia, Smoking) and the use of reno-protective agents such as ARBs and or ACEIs, may delay the progression of renal disease besides reducing the cardiovascular morbidity and mortality.
From our study, it shows that the most commonly prescribed drugs in patients suffering from Diabetic nephropathy with proteinuria are ARBs and ACE inhibitors beside the anti diabetic therapy. Among those, ARBs are more frequently prescribed than ACE Inhibitors.
Combination therapy of drugs was prescribed owing to the multifactorial etiology and pathogenesis of the disease. ARB with Diuretics or CCBs appeared to be the most commonly prescribed combination therapy.
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